A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 16, 2020

Primary Completion Date

December 13, 2027

Study Completion Date

December 13, 2027

Conditions

Progressive Supranuclear Palsy

Interventions

DRUG

UCB0107 (bepranemab)

UCB0107 (bepranemab) will be administered in a predefined dosage. Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous

Trial Locations (11)

Psp002 40122, Edegem

Psp002 40002, Leuven

Psp002 40277, Bochum

Psp002 40276, Düsseldorf

Psp002 40278, Essen

Psp002 40024, Hanover

Psp002 40267, Barcelona

Psp002 40100, Madrid

Psp002 40268, Pamplona

Psp002 40175, London

Psp002 40165, Southampton

All Listed Sponsors

lead

UCB Biopharma SRL

INDUSTRY